Doctor's Notes

Can Topical Care Control Moderate Pediatric Eczema Long Term? The ROAD Study

AI-generated illustration: Dr. Arsy Hydration Jar in Morning Light

Dr. Arsy Editorial Team · November 9, 2026

Parents may assume moderate-to-severe pediatric eczema always requires systemic treatment. The prospective ROAD cohort provides a more nuanced picture: many children improved substantially over 12 months with structured topical therapy, although the observational design cannot identify which part of care caused the change.[3]

Who was analyzed?

Of 763 enrolled children, 107 began with an EASI score of at least 7.1; 77 had complete EASI measurements at both follow-ups. Their median age was 57 months. Only two children required systemic therapy during the study.[3]

Clinical and family outcomes

Median EASI fell from 14.8 at baseline to 0.8 at both six and 12 months. EASI-75 was reached by 80.5% at six months and 85.7% at 12 months. Patient-reported symptoms, itch, sleep disturbance and quality-of-life scores also improved. These are strong within-cohort changes, but there was no randomized comparison group and 30 of 107 eligible children lacked complete follow-up data.

Why adherence and instruction matter

“Topical therapy” is not a single product. Outcomes can depend on correct diagnosis, treatment strength, body location, duration, proactive maintenance, moisturizer use, follow-up and whether caregivers are comfortable with instructions. Trials of proactive topical strategies and systematic reviews help explain why a detailed plan can differ from casual, inconsistent application.[20][21][22][23]

What families can ask

  • Which areas need moisturizer and which need prescription treatment?
  • What dose, duration and maintenance schedule should be followed?
  • How will itch, sleep and quality of life be tracked?
  • When is lack of improvement enough to reconsider the diagnosis or escalate care?
  • What signs suggest infection or an urgent review?

The ROAD study supports taking optimized topical care seriously, while leaving room for systemic treatment when disease remains uncontrolled or the burden is unacceptable.[14][16][17]

Moisturizer context

Dr. Arsy Moisturizer #003 supports cosmetic hydration for dry, sensitive and eczema-prone skin. It was not tested in the study above and does not reproduce the effects of prescription treatment, phototherapy or a care-delivery program.

Related research

Research and clinical references

  1. Narrowband versus broadband UVB randomized trial.
  2. Online versus in-person atopic dermatitis care randomized trial.
  3. ROAD study of long-term topical therapy in pediatric eczema.
  4. TRuE-AD3 52-week ruxolitinib cream study in children.
  5. Western Japan Atopic Dermatitis Registry design.
  6. Teledermatology in atopic dermatitis systematic review.
  7. Telemedicine in atopic dermatitis meta-analysis.
  8. Teledermatology versus in-person follow-up randomized trial.
  9. Web-based consultations for parents of children with eczema.
  10. Direct-access online care randomized clinical trial.
  11. Direct-access online care and quality of life trial.
  12. Phototherapy for atopic eczema: Cochrane review.
  13. AAD adult systemic therapy and phototherapy guideline.
  14. AAD pediatric atopic dermatitis management guideline.
  15. AAD adult topical therapy guideline.
  16. AAP skin-directed management clinical report.
  17. AAAAI/ACAAI atopic dermatitis guideline.
  18. Ruxolitinib cream TRuE-AD1 and TRuE-AD2 phase 3 trials.
  19. Pediatric ruxolitinib cream maximum-use trial.
  20. Long-term proactive topical corticosteroid strategy trial.
  21. Twice-weekly fluticasone maintenance in atopic dermatitis.
  22. Topical corticosteroids for atopic eczema: Cochrane review.
  23. Educational and psychological interventions for eczema: Cochrane review.
  24. Atopic dermatitis outcome measurement harmonization.

Educational information only; not medical advice. Cited researchers and organizations do not endorse Dr. Arsy products.

← Back to Doctor's Notes